Pfizer Inc. (PFE) Stock

NYSE
HealthcareDrug Manufacturers - General Website

PFE has an Alpha Score of 44 out of 100 (weak), computed on Nov 13, 2026 from 3 of 4 sub-scores. 61 members of Congress disclosed 204 trades in PFE since 2014: 85 purchases and 119 sales, most recently Tommy Tuberville (sale, Jun 8, 2026). 7 of the hedge funds AlphaScala tracks reported PFE in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is D.E. Shaw's at $473.00M. Its trailing P/E ratio is 41.5 and its net margin 6.3% (key statistics as of Nov 8, 2026).

$27.40
-0.51%
Last price
Source: Finnhub
Alpha Score
44
Weak

What is PFE's Alpha Score?

How it works →

Alpha Score of 44 reflects weak overall profile with moderate momentum, moderate value, poor quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.

Momentum
58
Moderate
Value
57
Moderate
Quality
29
Poor

Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.

Computed Nov 13, 2026

A rules-based research rating, not a recommendation to buy or sell.

Which members of Congress traded Pfizer Inc. (PFE)?

Members
61
Disclosed trades
204
Purchases
85
Sales
119

Most recent: Tommy Tuberville (sale, Jun 8, 2026); records start Apr 24, 2014.

PoliticianTrade dateTypeAmount
Tommy Tuberville
R-AL · Senate
2026-06-08sale$15k – $50k
Alan Armstrong
R-OK · Senate
2026-03-24sale$50k – $100k
Gil Cisneros
D-CA · House
2026-03-13partial sale$1k – $15k
Gil Cisneros
D-CA · House
2026-02-10purchase$1k – $15k
French Hill
R-AR · House
2025-12-31sale$100k – $250k
Gil Cisneros
D-CA · House
2025-12-19partial sale$1k – $15k
Gil Cisneros
D-CA · House
2025-11-18purchase$1k – $15k
Gil Cisneros
D-CA · House
2025-08-05partial sale$1k – $15k

From STOCK Act periodic transaction reports. House filings as of Nov 19, 2026.

Every member of Congress who traded PFE, with filing lags →

Which hedge funds own PFE?

From 13F filings
FundShares HeldPosition ValueChange vs prior Q
D.E. Shaw
David Shaw
16.58M$473.00M+206%
Citadel
Ken Griffin
4.74M$135.23M-23%
Marshall Wace3.79M$108.11M+372%
Renaissance Technologies
Jim Simons (founder)
1.99M$56.73MNEW
Millennium Management
Israel Englander
1.74M$49.60M+213%
Bridgewater Associates
Ray Dalio
478K$13.63M+165%
Maverick Capital
Lee Ainslie
97K$2.75MNEW

13F holdings as of Sep 30, 2026

Explore all tracked funds →

Are Pfizer Inc. insiders buying or selling?

SEC Form 4 filings
DateInsiderRoleTypeSharesValue
Aug 12, 26Bourla AlbertChairman & CEOBUY38.0K$1.0M
Aug 5, 26Buckley Mortimer JDirectorBUY37.6K$960K
Aug 5, 26Blaylock Ronald EDirectorBUY39.2K$999K
Aug 5, 26Damico Jennifer B.SVP & ControllerSELL3.3K$83K

SEC Form 4 filings as of Nov 20, 2026

See cluster-buy signals across all tickers →

What are PFE's key statistics?

P/E Ratio
41.54
EPS (TTM)
0.70
Dividend Yield
5.38%
Beta
0.28
Net Margin
6.34%
ROE
4.60%
Debt / Equity
0.75
52W High
$31.44
52W Low
$23.62

Key statistics as of Nov 8, 2026

How does PFE's valuation compare with the Healthcare sector?

MetricPFEHealthcare medianCompanies in median
P/E ratio41.529.1147
Net margin6.34%3.59%223
Return on equity4.60%3.41%255
Dividend yield (payers)5.38%1.37%61

Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 22, 2026). P/E excludes loss-making companies.

What did Pfizer Inc.'s latest SEC filings say?

Latest 1
10-KFeb 26, 2026SEC.gov →

Pfizer Reports 2025 Financial Results and Strategic Restructuring Initiatives

Pfizer Inc. filed its 2025 10-K, detailing a year of significant portfolio adjustments and cost-management programs. The company continues to navigate the integration of major acquisitions, including Seagen, while executing multiple restructuring plans aimed at optimizing its manufacturing footprint and overall cost base. Financial operations in 2025 were marked by ongoing investments in research and development, particularly in the biopharma segment, and the management of various collaborative arrangements and licensing agreements. The company reported activity related to its equity method investments, including divestitures of its stake in Haleon. Pfizer also entered into new strategic agreements, such as the November 2025 arrangement with Metsera, involving payments linked to clinical trial milestones and regulatory approvals. The company maintains a focus on its core biopharma operations, with ongoing efforts to streamline research and development and manufacturing processes. Asset impairments and restructuring charges remain a component of the company's financial profile as it aligns its cost structure with current strategic priorities. The filing highlights the company's reliance on a concentrated portfolio of products, with the top eleven to twelve products representing a significant portion of its revenue base. Management continues to monitor the impact of these restructuring programs on its long-term financial health and operational efficiency.

Material changes
  • ›Executed multiple cost-realignment and manufacturing optimization programs within the Biopharma segment.
  • ›Completed divestiture activities related to equity method investments in Haleon throughout 2025.
  • ›Entered into a strategic agreement with Metsera involving milestone-based payments for clinical and regulatory progress.
  • ›Continued integration of Seagen, including associated restructuring and acquisition-related costs.
  • ›Reported ongoing asset impairments and restructuring charges related to research and development and manufacturing.
  • ›Maintained high product concentration, with the top twelve products accounting for a significant revenue share.

AlphaScala analysis on PFE

Latest 1

PFE price chart

Powered by TradingView

What does Pfizer Inc. do?

Pfizer Inc. is a research-based global biopharmaceutical company founded in 1849 and headquartered in New York. It focuses on the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products worldwide, targeting developed and emerging markets to advance wellness, prevention, treatments, and cures for the most feared diseases. Operating in the health technology sector, specifically pharmaceuticals: major, Pfizer Inc. addresses critical areas such as oncology, rare diseases, internal medicine, inflammation and immunology, vaccines, anti-infectives, gene therapy, medicinal sciences, and precision medicine. Notable advancements include acquisitions like Global Blood Therapeutics in 2023 to bolster its biopharmaceutical portfolio, alongside recent clinical trial successes in prostate cancer, lung cancer, and bladder cancer therapies. With approximately 81,000 employees, Pfizer Inc. generates substantial revenue, reported at $63.63 billion for the fiscal year, and maintains a significant presence in the global market through innovative pipelines and partnerships.

CEO
Dr. Albert Bourla D.V.M., Ph.D.
Employees
75,000
Market Cap
$167.52B
Ask about PFEAI research agent